Menu
Search Close

News

Helium Special Situations increases interest in Scancell

17th November 2011

Scancell Holdings Plc

(‘Scancell Holdings’ or the ‘Company’)

 

Holdings in Company

The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.

 
 

For further information contact:

 

Scancell Holdings Plc 

Professor Lindy Durrant/Dr Richard Goodfellow

+ 44 (0)207 245 1100

Hansard Communications- Financial PR 

Adam Reynolds/Guy McDougall

+ 44 (0)207 245 1100

Zeus Capital - Nominated Adviser

Ross Andrews/Tom Rowley

+ 44 (0)161 831 1512

XCAP Securities Plc - Broker

Jon Belliss/ Adrian Kirk

+44 (0) 207 101 7070

Webcasts, Interviews and Media Coverage

Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Martin Diggle, co-founder of Vulpes Investment Management which manages the Vulpes Life Sciences Fund, discusses their recent investment into Scancell Holdings PLC (LON:SCLP).

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.

Fri, 21 Jun 2019 08:21:00

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00